Drug Trial Radar · NCT07913360
GFH375 Plus Cetuximab vs Investigator's Choice of Treatment in KRAS G12D-Mutant Refractory Metastatic Colorectal Cancer
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
368
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Nov 2028
Study completion May 2030
Sponsor
- Lead sponsor
- Genfleet Therapeutics (Shanghai) Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 3, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase III trial. All enrolled subjects are patients with metastatic colorectal cancer (mCRC) harboring KRAS G12D mutations who have previously received systemic therapy. The study aims to evaluate and compare the efficacy of GFH375 in combination with cetuximab versus the investigator's choice of treatment in participants with KRAS G12D mutant refractory metastatic colorectal cancer (mCRC).
Conditions
- Colorectal Cancer
Interventions
GFH375 + CetuximabDrug
GFH375:600 mg orally, once daily Cetuximab :500 mg/m² intravenously every 2 weeks
FruquintinibDrug
35 mg/m² orally twice daily (max single dose 80 mg) on Days 1-5 and Days 8-12
Trifluridine and TipiracilDrug
5 mg orally once daily on Days 1-21
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS)Time frame: Up to approximately 2 years
- Overall survival(OS)Time frame: Up to approximately three and a half years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.